Opioid and tachykinin systems are involved in modulation of pain transmission in the spinal cord. Regulation of surface opioid receptors on nociceptive afferents is critical for opioid analgesia. Plasma-membrane insertion of ␦-opioid receptors (DORs) is induced by stimulus-triggered exocytosis of DOR-containing large dense-core vesicles (LDCVs), but how DORs become sorted into the regulated secretory pathway is unknown. Here we report that direct interaction between protachykinin and DOR is responsible for sorting of DORs into LDCVs, allowing stimulus-induced surface insertion of DORs and DOR-mediated spinal analgesia. This interaction is mediated by the substance P domain of protachykinin and the third luminal domain of DOR. Furthermore, deletion of the preprotachykinin A gene reduced stimulus-induced surface insertion of DORs and abolished DOR-mediated spinal analgesia and morphine tolerance. Thus, protachykinin is essential for modulation of the sensitivity of nociceptive afferents to opioids, and the opioid and tachykinin systems are directly linked by protachykinin/DOR interaction.
Introduction
The opioid system serves inhibitory functions in pain transmission. δ-and -opioid receptors, homologous G protein-coupled receptors (Evans et Sorting signals have been identified for some membrane proteins of secretory granules, such as that found in the cytoplasmic domain of P-selectin (Disdier et al., 1992) . Although it has long been suggested that granule membrane proteins may be sorted to the granules by binding of their luminal domains to the granule content (Arvan and Castle, 1998; Kelly, 1985) , there is no direct evidence in support of this idea. In the present study, we investigated whether the sorting of DORs into LDCVs is due to the interaction with the granular content and found that direct binding of DOR with substance P-containing protachykinin, a content protein of LDCVs in small DRG neurons, is essential for the sorting.
Substance P is the first pronociceptive neuropeptide identified in small DRG neurons. Together with other tachykinin peptides, it is coded by the preprotachykinin A (PPT-A) gene (Chiwakata et al., 1991; Nawa et al., 1983) . Differential RNA splicing of primary PPT-A transcripts results in the production of three substance P-encoding mRNAs, α-, β-, and γ-PPT mRNAs, among which β-PPT (the precursor for both substance P and substance K) is expressed in small DRG neurons (Helke et al., 1990; Hökfelt et al., 1975) . Cleavage of the signal peptide from β-PPT in the endoplasmic reticulum yields protachykinin, which is transported to the trans-Golgi network, where it is sorted into LDCVs. Protachykinin undergoes further cleavage and other processing events within LDCVs to produce substance P and other mature peptides while LDCVs are being transported to the nerve terminals for secretion.
Small DRG neurons give rise to unmyelinated nociceptive afferents (C fibers). Substance P is transported to the peripheral and central terminals of C fibers and released after tissue damage or in response to nociceptive stimuli. Peripherally released substance P contributes to enhanced pain sensation indirectly via its proinflammatory effects, including vasodilatation and histamine release from mast cells (Helke et al., 1990; Woolf and Salter, 2000) . Substance P released from the central terminals acts on dorsal spinal-cord neurons expressing the substance P/neurokinin 1 receptor (Mantyh et al., 1995; Woolf and Salter, 2000) . However, the precise role of tachykinins in the nociceptive response of the spinal cord remains controversial because substance P-receptor antagonists cannot reduce human pain (Rupniak and Kramer, 1999), and the nociceptive defect in PPT-A knockout mice appears to be mainly involved in supraspinal mechanisms and peripheral proinflammatory effects (Cao et al., 1998; Zimmer et al., 1998) . In this study, we found that protachykinin directly interacts with DOR and that this interaction is responsible for sorting DORs into LDCVs. This novel action of protachykinin allows regulated insertion of DORs in C fibers upon nociceptive stimulation, enabling DOR-mediated spinal analgesia.
Results

DOR Localization in LDCVs Requires Preprotachykinin A Expression
The first clue to the mechanism of the LDCV localization of DORs came from the observation that DORs are always found to colocalize with substance P in a subpopulation of small DRG neurons. In mouse DRG, DOR is expressed in about half of the cells (Bao et al., 2003) , most of which are small neurons. In the subpopulation (w41%) of DOR-immunoreactive small neurons that contained substance P, DORs were consistently found in distinct substance P-containing LDCVs ( Figure 1A ).
In contrast, in those neurons (w59%) that did not contain substance P, DORs were found to be more diffusely distributed in the cytoplasm, some localized to vesicular structures ( Figure S1A ).
Further indication that PPT-A expression is important for the LDCV localization of DOR was provided by the finding that, in PPT-A knockout mice, DOR was absent in LDCVs. In wild-type small DRG neurons (n = 20), 83% ± 5% of DOR-immunoreactive LDCVs contained calcitonin gene-related peptide (CGRP), a neuropeptide that normally colocalizes with substance P in LDCVs (Zhang et al., 1995). In contrast, we found that DOR and CGRP were present in different vesicular compartments in small DRG neurons of PPT-A knockout mice ( Figure  1B) . Ultrastructural study showed that DORs were localized in multivesicular bodies that are known to be lysosomal compartments (Smith and Farquhar, 1966), suggesting that DORs excluded from LDCVs are processed for degradation ( Figure 1C ). This abnormal DOR localization in small DRG neurons of PPT-A knockout mice was DOR specific since the CGRP localization was unaffected ( Figure 1C ). It was also not caused by any change in DOR expression since the mRNA and protein level of DOR and the percentage of DOR-containing DRG neurons (w54%) were similar to those found in wild-type mice (Figures S1B-S1D).
Protachykinin Is Sufficient for Sorting DOR into LDCV
Having found that PPT-A expression is necessary for DOR sorting into LDCVs, we further inquired whether protachykinin is sufficient for the sorting process. The β-preprotachykinin protein (1-130 amino acid residues) and 2G) . Thus, the substance P domain is sufficient for conveying the localization signal to DOR, although it must act as part of a larger peptide backbone, which can be provided by either β-PPT(1-57) or α-CGRP (1-82).
The Substance P Domain of Protachykinin Interacts with DOR To further investigate the mechanism underlying protachykinin-mediated DOR sorting, we examined whether there is any interaction between DOR and the substance P domain. In experiments using HEK293 cells coexpressing substance P [β-PPT(58-68)] fused with green fluorescent protein (GFP) in the cytoplasm and HA-DOR in the cell membrane, we found that HA-DOR coimmunoprecipitated (CoIP) with substance P in the cell lysate ( Figures 3A and 3B) . Neither expressed CGRP-GFP nor neuropeptide Y-GFP CoIP with HA-DOR ( Figure 3A and data not shown). Whether endogenous DOR in neurosecretory cells interacts with the substance P domain was further examined in pheochromocytoma (PC12) cells and in mouse DRG neurons. Similar to small DRG neurons, PC12 cells contained LDCVs, and endogenous DORs were colocalized with substance P in LDCVs ( Figure 3C ). We applied the membrane-permeable crosslinker disuccinimidyl suberate in PC12 cells and in dissociated DRG neurons and found that endogenous DOR CoIP with substance P (Figures 3C and 3D ). These findings suggest that DOR interacts with the substance P domain of protachykinin. that, when D288A and D293A mutations were introduced into DOR(285-293), mutated MOR exhibited no LDCV localization (Figures 4A and 4D) . Taken together, these findings strongly support the notion that the third luminal domain of DOR is both necessary and sufficient for the LDCV localization.
The Third Luminal Domain of DOR Is Responsible for Sorting DOR to LDCV
Direct Interaction of the Substance P Domain with the Sorting Domain of DOR
The above studies demonstrated that both the substance P domain of protachykinin and the third luminal domain of DOR are critical for sorting DORs into LDCVs. We further inquired whether there is direct interaction between these two domains. In experiments using HEK293 cells coexpressing substance P (β-PPT(58-68))-GFP and HA-DOR, we found that these two proteins CoIP strongly in the cell lysate. However, the CoIP signal was greatly reduced when a mutated HA-DOR(D288A, D293A) was examined instead of HA-DOR ( Figure 5A) . In complementary experiments, we examined the effect of specific mutation of β-PPT(58-68) on CoIP with DOR. When positively charged arginine 58 in β-PPT(58-68) was mutated into noncharged alanine, its CoIP signal with DOR was reduced, and the reduction was more pronounced with an additional mutation at positively charged lysine 60 ( Figure 5B ), suggesting the importance of electrostatic interaction between β-PPT(58-68) and DOR. The interaction between DOR(285-293) and the substance P domain was further confirmed in PC12 cells. Following crosslinking with disuccinimidyl suberate, the amount of endogenous substance P CoIP with heterologously expressed DOR (D288A, D293A) was greatly reduced as compared to that found with HA-DOR ( Figure 5C ).
More definitive evidence for the direct binding of the third luminal domain of DOR to the substance P domain of protachykinin was provided by the pull-down assay using glutathione S-transferase (GST) fusion peptides. We found significant [ 3 H]substance P binding with GST-DOR(281-301) but not with GST-fused DOR(105-123) and DOR(184-213), two regions roughly corresponding to the first and second luminal domain, respectively ( Figure 5D ). Double-mutation D288A and D293A in GST-DOR(281-301) disrupted the specific binding with substance P ( Figure 5D ). These results indicate that the sorting domain of DOR directly interacts with the substance P domain of protachykinin.
Impaired DOR Trafficking in Small DRG Neurons of PPT-A Knockout Mice
Given that tachykinin plays an essential role in sorting DOR into the regulated pathway, we further examined the effect of PPT-A knockout on the DOR trafficking in small DRG neurons. Our previous study showed that the selective DOR agonist deltorphin I (Erspamer et al.,  1989) , or the vanilloid-receptor agonist capsaicin, induces the plasma-membrane insertion of LDCV-associated DORs in these neurons (Bao et al., 2003) . However, in the present study, we found that this agonist-induced DOR insertion was eliminated in small DRG neurons from PPT-A knockout mice ( Figures 6A and 6B) , indicating that DORs are not present in the regulated pathway.
Small DRG neurons give rise to afferent C fibers that terminate in laminae I-II in the dorsal horn of the spinal cord ( Figure 6C ). Western blotting showed that DOR was expressed in the dorsal horn of the spinal cord ( Figure 6D ). Both immunolabeling and measurements of agonist binding sites using [ Figures 6E and 6F) , consistent with the reports on the presence of DOR in C fiber terminals (Besse et al., 1992; Fields et al., 1980) . However, in laminae I-II of the spinal cord of PPT-A knockout mice, the DOR level was significantly reduced (Figures 6D-6F) . This reduction in DOR is specific since the immunolabeling of MORs and γ-aminobutyric acid B-receptor subunit 2 in these laminae was not changed (Figure S4) . At the ultrastructural level, we found that DORs were not associated with LDCVs in the axonal terminals in lamina II of the spinal cord of these mice but with some lucent endosome-like vesicles ( Figure 6G) , suggesting that the reduction in the DOR level may be due to the decrease in the DOR transport via LDCVs.
H]deltorphin I (Kitchen et al., 1997) showed DOR accumulation in laminae I-II of the spinal cord (
Importance of DOR Sorting for Spinal Analgesia
The functional importance of DOR sorting to the regulated pathway was further examined by studying spinal DOR-mediated analgesia. The DORs in C fiber terminals are known to be involved in analgesia at the spinal-cord level ( Figure 7B ). This effect is specifically caused by DOR deficiency rather than a nonspecific reduction of the responsiveness of the knockout mice because dose-dependent spinal analgesia was induced in these mice by intrathecal injection of morphine, which primarily acts on MORs, and by a low dose of the γ-aminobutyric acid B-receptor agonist baclofen ( Figure 7C ) (Hylden and Wilcox, 1980; Wilson and Yaksh, 1978) . In PPT-A knockout mice, intrathecal morphine-induced analgesia was in fact enhanced (Figure 7C) . The median effective dose (ED 50 ) for morphine analgesia was significantly lower [ED 50 = 0.09 g, with 95% confidence limits (0.04-0.22 g)] than that in wildtype mice [ED 50 = 0.40 g, (0.24-0.70 g)]. Thus, spinal DOR-mediated analgesia was specifically impaired in PPT-A knockout mice.
Interestingly, we found that morphine tolerance was absent in PPT-A knockout mice ( Figure 7D ). This is in sharp contrast to wild-type mice, in which the analgesic response to daily subcutaneous administration of morphine (5 mg/kg) was lost within 5 days ( Figure 7D ). After 10 days of chronic morphine administration, cumulative dose-response curves showed a significant 3.7-fold shift to the right of the morphine ED 50 in wild-type mice, while the potency of morphine in PPT-A knockout mice remained unchanged (Table S1 ). These data are consistent with previous reports that mice lacking DOR or its endogenous ligand enkephalin do not develop analgesic tolerance to morphine (Nitsche et al., 2002; Zhu et al., 1999) . This suggests that the DORs sorted into LDCVs by protachykinin are involved in the development of morphine tolerance.
Discussion
The present study demonstrates a link between the tachykinin and opioid systems that are involved in modulation of pain transmission in the spinal cord. We found that, in small DRG neurons, sorting of DORs into the regulated pathway requires preprotachykinin expression. The sorting domain was found to locate within the third luminal domain of DOR, and its interaction with the substance P domain of protachykinin was essential for sorting DORs into LDCVs (see model in Figure 8 ). This sorting of DORs allows regulated insertion of DORs in response to nociceptive stimuli. Our findings delineate not only a molecular mechanism for selective sorting of a specific cell-surface receptor into the regulated pathway but also the cell biological basis for the modulation of opioid analgesia, including DORmediated analgesia and morphine tolerance.
Essential Role of the Substance P Domain in Protachykinin for DOR Sorting
In this study, the importance of protachykinin for DOR sorting was first suggested by the finding that LDCV localization of DORs was absent in small DRG neurons from PPT-A knockout mice. This requirement of PPT for DOR sorting was further confirmed by heterologous coexpression of β-PPT with DOR in HEK293 cells in which LDCVs were reconstituted by coexpression of chromogranin A. Interestingly, coexpression of DOR with a mutated α-CGRP in which the CGRP domain was substituted with the substance P domain resulted in DOR localization in reconstituted LDCVs. Thus, the substance P domain in a different polypeptide environment provided by another granule content protein α-CGRP is sufficient to convey the localization signal for DOR. The evidence from CoIP and binding experiments further supports the notion that the substance P domain interacts directly with the sorting domain of DOR. Thus, during the formation of LDCVs in the transGolgi network, protachykinin plays a critical role of presenting the substance P domain for the interaction with DOR, leading to DOR sorting into LDCVs (see model in 
Cell-Surface Biotinylation and Western Blotting
According to our previous protocol (Bao et al., 2003) , biotinylation of neurons was carried out at 37°C for 10 min in the presence of 1 M deltorphin or capsaicin followed by biotinylation at 4°C for 45 min. Mouse DRG and the dorsal spinal cord were sonicated/ homogenized and centrifuged. The samples were loaded on SDS-PAGE, transferred, probed with antibodies, and visualized with enhanced chemiluminescence. Antibodies against DOR (1:3,000), substance P (1:1,000), HA (1:1,000), Myc (1:1000), GFP (1:3,000), and actin (1:10,000) were used. Immunoblot was analyzed with NIH image program (mean ± SEM and unpaired t test). 
Receptor Autoradiography
